Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2007

View Archived Issues

Positive results for Regeneron's proof-of-concept study of rilonacept for gout / News in Context

Novel CXCR2 antagonist useful in models of acute and chronic inflammation

GenVec signs CRADA for malaria vaccine development

ProMetic Life Sciences expands PBI-1402 program to include cancer-related anemia

Positive results for Renovo's phase II trial of Juvista for treatment of wounds and scars

New antipsychotic, antidepressive and anxiolytic agents cited in patent literature

CRT, UCL and Novozymes to codevelop novel anticancer therapeutics

FDA opens Corcept's IND for Corlux for Cushing's syndrome allowing initiation of phase III study

Estrogen-dependent breast cancer growth in vivo suppressed by KW-2581

New compounds for treatment of HCV infection revealed

Recent patents impart new therapeutic agents for cancer

FDA Advisory Committees reaffirm current dosing practices for ESAs

Inhibitex licenses HIV integrase and hepatitis C polymerase inhibitors from UGARF

Phenomix begins phase IIb trial of PHX-1149 for type 2 diabetes

Phosphagenics to initiate phase II trials of TMP/Insulin for diabetes

BioSante and FDA reach agreement on LibiGel development requirements

Update on Aspreva and Roche's development of CellCept for lupus nephritis

Nventa begins phase I trial of HspE7 dosed with an adjuvant for CIN

Positive results for Chelsea's new formulation of CH-1504 for RA

Trubion reports preliminary analysis of phase IIb trial of TRU-015 for RA

New drug targets in neuropathic pain described

Minocycline shows neuroprotection in animal models of Alzheimer's disease

Pivotal phase III prophylactic HAE trial of Cinryze meets primary endpoint

FDA grants Metabasis' MB-07133 orphan drug designation for HCC

Novartis launches daptomycin for MSSA and MRSA bloodstream and heart infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...